OPT Share Price Performance
AU$0.60
-0.08 (-11.11%)
86.6% undervalued intrinsic discount
AU$4.48
Fair Value
Price AU$0.60
StockMan AU$4.48
Bailey AU$0.61
Fair ValueAU$0.10
Share Pricen/a
Opthea Limited Stock Price
- 2 Narratives written by author
- 2 Comments on narratives written by author
- 51 Fair Values set on narratives written by author
OPT Community Narratives
ST
Fair Value AU$0.1 500.0% overvalued intrinsic discount
OPTHEA - Write-off
17users have liked this narrative
2users have commented on this narrative
27users have followed this narrative
BA
Fair Value AU$0.61 1.6% undervalued intrinsic discount
Opthea Test
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
OPTHEA - Write-off
--- [Narrative update per Investor announcement 24-Mar-2025] --- The analysis below was written ahead of Opthea’s Phase 3 results. As stated, the thesis was highly dependent on trial success.Read more
1.2k
users have viewed this narrative17users have liked this narrative
2users have commented on this narrative
27users have followed this narrative
ST
AU$0.1
500.0% overvalued intrinsic discount
StockMan's Fair Value
Profit Margin
100%
Future PE
500x
Price in 2034
AU$0.24
Opthea Test
Key takeaways: Opthea's sozinibercept (in phase 3 trials) offers a breakthrough in eye care as a complementary treatment that could significantly improve outcomes for wet AMD patients alongside existing therapies. Wet AMD treatment is a $15 Billion global market,.With no other product in the pipeline addressing the same mechanism of action, Opthea is strategically positioned as a unique player in the market.Read more
3
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Trending Discussion
Recently Updated Narratives
ST
OPTHEA - Write-off
Fair Value: AU$0.1 500.0% overvalued intrinsic discount
27 followersusers have followed this narrative
2 commentsusers have commented on this narrative
0 likesusers have liked this narrative
BA
Opthea Test
Fair Value: AU$0.61 1.6% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Opthea Limited Key Details
Last Reported Earnings
Dec 30, 2024
Next Reporting Earnings
n/a
- -0.20
- 100.00%
- -119,924.98%
- -132.0%
About OPT
- Founded
- 1984
- Employees
- 33
- CEO
- WebsiteView website
Opthea Limited, a clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States. Its development activities are based on the intellectual property portfolio covering vascular endothelial growth factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company’s lead product candidate is sozinibercept (OPT-302), a biologic drug in Phase 3 clinical trials designed to inhibit VEGF-C and VEGF-D and complement VEGF-A inhibitors for the treatment of wet age-related macular degeneration and diabetic macular edema. It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in South Yarra, Australia.
